Skip to main content
Top
Published in: Annals of Hematology 1/2013

01-01-2013 | Original Article

Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification

Authors: P. Font, J. Loscertales, C. Benavente, A. Bermejo, M. Callejas, L. Garcia-Alonso, A. Garcia-Marcilla, S. Gil, M. Lopez-Rubio, E. Martin, C. Muñoz, P. Ricard, C. Soto, P. Balsalobre, A. Villegas

Published in: Annals of Hematology | Issue 1/2013

Login to get access

Abstract

Morphology is the basis of the diagnosis of myelodysplastic syndromes (MDS). The WHO classification offers prognostic information and helps with the treatment decisions. However, morphological changes are subject to potential inter-observer variance. The aim of our study was to explore the reliability of the 2008 WHO classification of MDS, reviewing 100 samples previously diagnosed with MDS using the 2001 WHO criteria. Specimens were collected from 10 hospitals and were evaluated by 10 morphologists, working in five pairs. Each observer evaluated 20 samples, and each sample was analyzed independently by two morphologists. The second observer was blinded to the clinical and laboratory data, except for the peripheral blood (PB) counts. Nineteen cases were considered as unclassified MDS (MDS-U) by the 2001 WHO classification, but only three remained as MDS-U by the 2008 WHO proposal. Discordance was observed in 26 of the 95 samples considered suitable (27 %). Although there were a high number of observers taking part, the rate of discordance was quite similar among the five pairs. The inter-observer concordance was very good regarding refractory anemia with excess blasts type 1 (RAEB-1) (10 of 12 cases, 84 %), RAEB-2 (nine of 10 cases, 90 %), and also good regarding refractory cytopenia with multilineage dysplasia (37 of 50 cases, 74 %). However, the categories with unilineage dysplasia were not reproducible in most of the cases. The rate of concordance with refractory cytopenia with unilineage dysplasia was 40 % (two of five cases) and 25 % with RA with ring sideroblasts (two of eight). Our results show that the 2008 WHO classification gives a more accurate stratification of MDS but also illustrates the difficulty in diagnosing MDS with unilineage dysplasia.
Literature
2.
go back to reference Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW, Hellstrom-Lindberg E (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 88–93 Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW, Hellstrom-Lindberg E (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 88–93
3.
go back to reference Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL (2001) Myelodysplastic syndromes. Introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 63–67 Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL (2001) Myelodysplastic syndromes. Introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 63–67
4.
go back to reference Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951PubMedCrossRef Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951PubMedCrossRef
5.
go back to reference Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270PubMedCrossRef Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270PubMedCrossRef
6.
go back to reference Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z et al (2011) Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118:4690–4693PubMedCrossRef Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z et al (2011) Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118:4690–4693PubMedCrossRef
7.
go back to reference Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed
8.
go back to reference Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) French–American–British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) French–American–British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMed
9.
go back to reference Verburgh E, Achten R, Louw VJ, Brusselmans C, Delforge M, Boogaerts M et al (2007) A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia 21:668–677PubMed Verburgh E, Achten R, Louw VJ, Brusselmans C, Delforge M, Boogaerts M et al (2007) A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia 21:668–677PubMed
10.
go back to reference Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R et al (2008) Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717PubMedCrossRef Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R et al (2008) Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717PubMedCrossRef
11.
go back to reference Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510PubMedCrossRef Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510PubMedCrossRef
12.
go back to reference Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A et al (2007) Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia 21:678–686PubMed Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A et al (2007) Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia 21:678–686PubMed
13.
go back to reference Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983–992PubMedCrossRef Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983–992PubMedCrossRef
14.
go back to reference Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596–1604PubMed Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596–1604PubMed
15.
go back to reference Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP et al (2012) Prognostic irrelevance of ring sideroblast percentage in World Health Organization defined myelodysplastic syndromes without excess blasts. Blood 119:5674–5677PubMedCrossRef Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP et al (2012) Prognostic irrelevance of ring sideroblast percentage in World Health Organization defined myelodysplastic syndromes without excess blasts. Blood 119:5674–5677PubMedCrossRef
16.
go back to reference Kantarjian H, O’Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351–1361PubMedCrossRef Kantarjian H, O’Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351–1361PubMedCrossRef
Metadata
Title
Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification
Authors
P. Font
J. Loscertales
C. Benavente
A. Bermejo
M. Callejas
L. Garcia-Alonso
A. Garcia-Marcilla
S. Gil
M. Lopez-Rubio
E. Martin
C. Muñoz
P. Ricard
C. Soto
P. Balsalobre
A. Villegas
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 1/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1565-4

Other articles of this Issue 1/2013

Annals of Hematology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.